Raymond L Woosley

List of Publications by Year
in descending order

211	11,398	29994 54	31759 101
papers	citations	h-index	g-index

215	215	215	6599
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Incidence and clinical features of the quinidine-associated long QT syndrome: Implications for patient care. American Heart Journal, 1986, 111, 1088-1093.	1.2	498
2	Mechanism of the Cardiotoxic Actions of Terfenadine. JAMA - Journal of the American Medical Association, 1993, 269, 1532.	3.8	498
3	Effect of Acetylator Phenotype on the Rate at Which Procainamide Induces Antinuclear Antibodies and the Lupus Syndrome. New England Journal of Medicine, 1978, 298, 1157-1159.	13.9	386
4	The FDA Critical Path Initiative and Its Influence on New Drug Development. Annual Review of Medicine, 2008, 59, 1-12.	5.0	384
5	Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin. Clinical Pharmacology and Therapeutics, 1992, 52, 231-238.	2.3	362
6	Sex Hormones Prolong the QT Interval and Downregulate Potassium Channel Expression in the Rabbit Heart. Circulation, 1996, 94, 1471-1474.	1.6	323
7	Influence of Opioid Agonists on Cardiac HumanEther-a-go-go-related Gene K+Currents. Journal of Pharmacology and Experimental Therapeutics, 2002, 303, 688-694.	1.3	238
8	Predicting the Unpredictable. Journal of the American College of Cardiology, 2016, 67, 1639-1650.	1.2	227
9	QTc interval prolongation associated with intravenous methadone. Pain, 2003, 105, 499-506.	2.0	209
10	QT prolongation and torsades de pointes among methadone users: reports to the FDA spontaneous reporting system. Pharmacoepidemiology and Drug Safety, 2005, 14, 747-753.	0.9	198
11	Female Gender as a Risk Factor for Drug-Induced Cardiac Arrhythmias: Evaluation of Clinical and Experimental Evidence. Journal of Women's Health, 1998, 7, 547-557.	0.9	194
12	Intravenous amiodarone for recurrent sustained hypotensive ventricular tachyarrhythmias. Journal of the American College of Cardiology, 1996, 27, 67-75.	1.2	191
13	Total Suppression of Ventricular Arrhythmias by Encainide. New England Journal of Medicine, 1980, 302, 877-882.	13.9	189
14	Cardiac Actions of Erythromycin. JAMA - Journal of the American Medical Association, 1998, 280, 1774.	3.8	186
15	Sotalol. New England Journal of Medicine, 1994, 331, 31-38.	13.9	181
16	Gadolinium Decreases Stretch-Induced Vulnerability to Atrial Fibrillation. Circulation, 2000, 101, 2200-2205.	1.6	175
17	Flecainide. New England Journal of Medicine, 1986, 315, 36-41.	13.9	172
18	Grapefruit juice alters terfenadine pharmacokinetics, resulting in prolongation of repolarization on the electrocardiogram*. Clinical Pharmacology and Therapeutics, 1996, 59, 383-388.	2.3	171

#	Article	IF	Citations
19	Inappropriate Prescribing for Elderly Americans in a Large Outpatient Population. Archives of Internal Medicine, 2004, 164, 1621.	4.3	170
20	Suppression of resistant ventricular arrhythmias by twice daily dosing with flecainide. American Journal of Cardiology, 1981, 48, 1133-1140.	0.7	164
21	Prescription of QT-prolonging drugs in a cohort of about 5 million outpatients. American Journal of Medicine, 2003, 114, 135-141.	0.6	164
22	Antiarrhythmic efficacy, pharmacokinetics and safety of N-acetylprocainamide in human subjects: Comparison with procainamide. American Journal of Cardiology, 1980, 46, 463-468.	0.7	157
23	The hydroxylation of omeprazole correlates with S-mephenytoin metabolism: A population study*. Clinical Pharmacology and Therapeutics, 1995, 57, 662-669.	2.3	149
24	Bazett and Fridericia QT correction formulas interfere with measurement of drug-induced changes in QT interval. Heart Rhythm, 2006, 3, 1003-1007.	0.3	145
25	The Role of Genetically Determined Polymorphic Drug Metabolism in the Beta-Blockade Produced by Propafenone. New England Journal of Medicine, 1990, 322, 1764-1768.	13.9	144
26	The cardiac arrhythmia suppression trial: First CAST â€¦ then CAST-II. Journal of the American College of Cardiology, 1992, 19, 894-898.	1.2	140
27	Greater quinidine-induced QTc interval prolongation in women. Clinical Pharmacology and Therapeutics, 2000, 67, 413-418.	2.3	138
28	Comparative Evaluation of HERG Currents and QT Intervals following Challenge with Suspected Torsadogenic and Nontorsadogenic Drugs. Journal of Pharmacology and Experimental Therapeutics, 2006, 316, 1098-1106.	1.3	135
29	In vivo androgen treatment shortens the QT interval and increases the densities of inward and delayed rectifier potassium currents in orchiectomized male rabbits. Cardiovascular Research, 2003, 57, 28-36.	1.8	134
30	N-Acetylation phenotype and genotype and risk of bladder cancer in benzidine-exposed workers. Carcinogenesis, 1993, 14, 675-678.	1.3	127
31	Making Medicines Safer â€" The Need for an Independent Drug Safety Board. New England Journal of Medicine, 1998, 339, 1851-1854.	13.9	123
32	Prolongation of QT Interval in Isolated Feline Hearts by Antipsychotic Drugs. Journal of Clinical Psychopharmacology, 1998, 18, 477-481.	0.7	120
33	Withdrawal of Haloperidol, Thioridazine, and Lorazepam in the Nursing Home. Archives of Internal Medicine, 1999, 159, 1733.	4.3	100
34	Concentration-dependent pharmacologic properties of sotalol. American Journal of Cardiology, 1986, 57, 1160-1165.	0.7	99
35	Pharmacist Workload and Pharmacy Characteristics Associated With the Dispensing of Potentially Clinically Important Drug-Drug Interactions. Medical Care, 2007, 45, 456-462.	1.1	98
36	Prescribers??? Knowledge of and Sources of Information for Potential??Drug-Drug Interactions. Drug Safety, 2008, 31, 525-536.	1.4	94

#	Article	IF	Citations
37	Antiarrhythmic effects of a lidocaine congener, tocainide, 2-amino-2',6'-propionoxylidide, in man. Clinical Pharmacology and Therapeutics, 1976, 19, 396-402.	2.3	90
38	Electrophysiologic Features of Torsades de Pointes:.. Journal of Cardiovascular Electrophysiology, 1997, 8, 1148-1158.	0.8	90
39	Cumulation of Nâ€acetylprocainamide, an active metabolite of procainamide, in patients with impaired renal function. Clinical Pharmacology and Therapeutics, 1977, 22, 63-69.	2.3	85
40	Geographic Variation in the Prescription of Schedule II Opioid Analgesics among Outpatients in the United States. Health Services Research, 2006, 41, 837-855.	1.0	83
41	Amiodarone dosing: A proposal based on its pharmacokinetics. American Heart Journal, 1983, 106, 951-956.	1.2	82
42	Clinical features and basic mechanisms of quinidine-induced arrhythmias. Journal of the American College of Cardiology, 1986, 8, 73A-78A.	1.2	82
43	Mechanism of cardiotoxicity of halofantrine. Clinical Pharmacology and Therapeutics, 2000, 67, 521-529.	2.3	79
44	Clinical pharmacology of propafenone: Pharmacokinetics, metabolism and concentration-response relations. American Journal of Cardiology, 1984, 54, 9D-12D.	0.7	75
45	CredibleMeds.org: What does it offer?. Trends in Cardiovascular Medicine, 2018, 28, 94-99.	2.3	74
46	Tocainide. New England Journal of Medicine, 1986, 315, 41-45.	13.9	73
47	Safe drug use in long QT syndrome and Brugada syndrome: comparison of website statistics. Europace, 2013, 15, 1042-1049.	0.7	69
48	Co-inheritance of the polymorphic metabolism of encainide and debrisoquin. Clinical Pharmacology and Therapeutics, 1986, 39, 282-287.	2.3	67
49	Female Gender is a Risk Factor for Torsades de Pointes in an In Vitro Animal Model. Journal of Cardiovascular Pharmacology, 1999, 34, 287-294.	0.8	65
50	Coupling Data Mining and Laboratory Experiments to Discover Drug Interactions Causing QT Prolongation. Journal of the American College of Cardiology, 2016, 68, 1756-1764.	1.2	63
51	Acetylator Phenotype and Lupus Erythematosus. Clinical Pharmacokinetics, 1981, 6, 118-134.	1.6	62
52	The electrocardiographic effects of cetirizine in normal subjects. Clinical Pharmacology and Therapeutics, 1994, 56, 295-301.	2.3	62
53	Pharmacokinetics of Sertraline Across Pregnancy and Postpartum. Journal of Clinical Psychopharmacology, 2008, 28, 646-653.	0.7	59
54	Salivary analysis for determination of dextromethorphan metabolic phenotype. Clinical Pharmacology and Therapeutics, 1991, 49, 410-419.	2.3	55

#	Article	IF	Citations
55	Testosterone-mediated modulation of HERG blockade by proarrhythmic agents11Abbreviations: TdP, torsades de pointes; HERG, human ether-a-go-go related gene; DMSO, dimethyl sulfoxide.. Biochemical Pharmacology, 2001, 62, 41-49.	2.0	55
56	Altered distribution of debrisoquine oxidation phenotypes in patients with systemic lupus erythematosus. Arthritis and Rheumatism, 1986, 29, 843-850.	6.7	54
57	Plasma concentrations of quinidine, its major metabolites, and dihydroquinidine in patients with torsades de pointes. Clinical Pharmacology and Therapeutics, 1988, 43, 636-642.	2.3	54
58	QT interval: A measure of drug action. American Journal of Cardiology, 1993, 72, B36-B43.	0.7	54
59	Guanethidine. New England Journal of Medicine, 1976, 295, 1053-1057.	13.9	53
60	Correlation between N-acetyltransferase activity and NAT2 genotype in Chinese male. Pharmacogenetics and Genomics, 1993, 3, 250-255.	5.7	51
61	Effects of congestive heart failure on the pharmacokinetics and pharmacodynamics of antiarrhythmic agents. American Journal of Cardiology, 1986, 57, B25-B33.	0.7	50
62	Differential Effects of D-Sotalol, Quinidine, and Amiodarone on Dispersion of Ventricular Repolarization in the Isolated Rabbit Heart. Journal of Cardiovascular Electrophysiology, 1997, 8, 1239-1245.	0.8	50
63	The Coalition Against Major Diseases: Developing Tools for an Integrated Drug Development Process for Alzheimerâ€™s and Parkinsonâ€™s Diseases. Clinical Pharmacology and Therapeutics, 2009, 86, 365-367.	2.3	49
64	Pharmacokinetics of antiarrhythmic drugs. American Journal of Cardiology, 1978, 41, 986-995.	0.7	48
65	Electrophysiologic actions of high plasma concentrations of propranolol in human subjects. Journal of the American College of Cardiology, 1983, 2, 1134-1140.	1.2	48
66	Terfenadine Increases the QT Interval in Isolated Guinea Pig Heart. Journal of Cardiovascular Pharmacology, 1995, 25, 30-34.	0.8	48
67	Is Dispersion of Ventricular Repolarization Rate Dependent?. PACE - Pacing and Clinical Electrophysiology, 1997, 20, 2405-2411.	0.5	47
68	Warfarin Interactions With Substances Listed in Drug Information Compendia and in the FDA-Approved Label for Warfarin Sodium. Clinical Pharmacology and Therapeutics, 2009, 86, 425-429.	2.3	45
69	Pharmacokinetics and pharmacodynamics of antiarrhythmic agents in patients with congestive heart failure. American Heart Journal, 1987, 114, 1280-1291.	1.2	44
70	Proarrhythmia, arrhythmogenesis or aggravation of arrhythmiaâ€”A status report, 1987. American Journal of Cardiology, 1987, 59, E54-E56.	0.7	44
71	Administration of Prostacyclin Prevents Ventricular Fibrillation Following Coronary Occlusion in Conscious Dogs. Journal of Cardiovascular Pharmacology, 1982, 4, 765-769.	0.8	42
72	Drug Labeling Revisionsâ€”Guaranteed to Fail?. JAMA - Journal of the American Medical Association, 2000, 284, 3047.	3.8	42

#	Article	IF	Citations
73	Possible interethnic differences in quinidine-induced QT prolongation between healthy Caucasian and Korean subjects. British Journal of Clinical Pharmacology, 2007, 63, 206-215.	1.1	42
74	Research at the interface of industry, academia and regulatory science. Nature Biotechnology, 2010, 28, 432-433.	9.4	40
75	Clinical Pharmacokinetics of Disopyramide. Clinical Pharmacokinetics, 1986, 11, 214-222.	1.6	38
76	Clinical implications of variable antiarrhythmic drug metabolism. Pharmacogenetics and Genomics, 1992, 2, 2-11.	5.7	38
77	P-Glycoprotein in Clinical Cardiology. Circulation, 1999, 99, 472-474.	1.6	38
78	Adverse Drug Event Causality Analysis (ADECA): A Process for Evaluating Evidence and Assigning Drugs to Risk Categories for Sudden Death. Drug Safety, 2017, 40, 465-474.	1.4	38
79	Use of herbal remedies by diabetic Hispanic women in The southwestern United States. Phytotherapy Research, 2006, 20, 250-255.	2.8	37
80	Visual Hallucination and Tremor Induced by Sertraline and Oxycodone in a Bone Marrow Transplant Patient. Journal of Clinical Pharmacology, 2001, 41, 224-227.	1.0	36
81	The roles of CYP2D6 and stereoselectivity in the clinical pharmacokinetics of chlorpheniramine. British Journal of Clinical Pharmacology, 2002, 53, 519-525.	1.1	36
82	Assessing cardiovascular drug safety for clinical decision-making. Nature Reviews Cardiology, 2013, 10, 330-337.	6.1	36
83	Potential Determinants of Prescribers' Drug-Drug Interaction Knowledge. Research in Social and Administrative Pharmacy, 2008, 4, 355-366.	1.5	34
84	Spectrum of antiarrhythmic response to encainide. American Journal of Cardiology, 1985, 56, 887-891.	0.7	33
85	Centers for Education and Research in Therapeutics. Clinical Pharmacology and Therapeutics, 1994, 55, 249-255.	2.3	33
86	Disposition kinetics of encainide and metabolites. American Journal of Cardiology, 1986, 58, C4-C9.	0.7	32
87	Prognostic significance of ventricular premature depolarizations measured 1 year after myocardial infraction in patient with early postinfarction asymptomatic ventricular arrhythmia. Journal of the American College of Cardiology, 1992, 20, 259-264.	1.2	32
88	Chlorpheniramine plasma concentration and histamine H1-receptor occupancy*. Clinical Pharmacology and Therapeutics, 1995, 58, 210-220.	2.3	32
89	Diagramming patientsâ€™ views of root causes of adverse drug events in ambulatory care: An online tool for planning education and research. Patient Education and Counseling, 2006, 62, 302-315.	1.0	32
90	QT prolongation and arrhythmia suppression. American Heart Journal, 1985, 109, 411-415.	1.2	31

#	Article	IF	Citations
91	Differential effects of O-demethyl encainide on induced and spontaneous arrhythmias in the conscious dog. American Journal of Cardiology, 1984, 54, 654-658.	0.7	30
92	Flecainide dose-response relations in stable ventricular arrhythmias. American Journal of Cardiology, 1984, 53, B59-B65.	0.7	30
93	Electrophysiologic effects of intravenous and oral sotalol for sustained ventricular tachycardia secondary to coronary artery disease. American Journal of Cardiology, 1988, 61, 1006-1011.	0.7	30
94	Pharmacogenetic characteristics of the eosinophilia-myalgia syndrome. Clinical Pharmacology and Therapeutics, 1994, 56, 398-405.	2.3	30
95	An Integrative Data Science Pipeline to Identify Novel Drug Interactions that Prolong the QT Interval. Drug Safety, 2016, 39, 433-441.	1.4	30
96	Normal distribution of acetylation phenotypes in systemic lupus erythematosus. Arthritis and Rheumatism, 1978, 21, 192-195.	6.7	29
97	Potential drugâ€“drug interactions within Veterans Affairs medical centers. American Journal of Health-System Pharmacy, 2007, 64, 1500-1505.	0.5	29
98	Pharmacokinetics of moricizine HCl. American Journal of Cardiology, 1987, 60, 35-39.	0.7	28
99	Overview of the clinical pharmacology of antiarrhythmic drugs. American Journal of Cardiology, 1988, 61, A61-A69.	0.7	28
100	Encainide disposition in patients with renal failure. Clinical Pharmacology and Therapeutics, 1986, 40, 64-70.	2.3	27
101	Encainide disposition in patients with chronic cirrhosis. Clinical Pharmacology and Therapeutics, 1986, 40, 148-154.	2.3	25
102	Pharmacokinetic, pharmacodynamic, and safety evaluation of an accelerated dose titration regimen of sotalol in healthy middle-aged subjects. Clinical Pharmacology and Therapeutics, 1999, 66, 91-99.	2.3	25
103	Comparison of the effects of placebo and encainide on programmed electrical stimulation and ventricular arrhythmia frequency. American Journal of Cardiology, 1982, 50, 305-312.	0.7	24
104	Pharmacokinetics and nondialyzability of mexiletine in renal failure. Clinical Pharmacology and Therapeutics, 1985, 37, 649-653.	2.3	24
105	Further evidence for the lack of association between acetylator phenotype and systemic lupus erythematosus. Arthritis and Rheumatism, 1986, 29, 508-514.	6.7	24
106	Gender and Age Differences in Medications Dispensed from a National Chain Drugstore. Journal of Women's Health, 2008, 17, 735-743.	1.5	24
107	Pharmacologic causes of arrhythmogenic actions of antiarrhythmic drugs. American Journal of Cardiology, 1987, 59, E19-E25.	0.7	23
108	Assessment and reporting of clinical pharmacology information in drug labeling. Clinical Pharmacology and Therapeutics, 2000, 67, 196-200.	2.3	23

#	Article	IF	Citations
109	Development of a comprehensive detection method for medicinal and toxic plant species. American Journal of Botany, 2006, 93, 566-574.	0.8	23
110	The implications of procainamide metabolism to its induction of lupus. Arthritis and Rheumatism, 1981, 24, 994-999.	6.7	22
111	Relationship of CYP2D6 (debrisoquine hydroxylase) genotype to breast cancer susceptibility. Pharmacogenetics and Genomics, 1993, 3, 322-327.	5.7	21
112	Amiodarone-Induced Lymphocyte Toxicity and Mitochondrial Function. Journal of Cardiovascular Pharmacology, 1996, 28, 94-100.	0.8	21
113	Mexiletine and tocainide: A comparison of antiarrhythmic efficacy, adverse effects, and predictive value of lidocaine testing. Clinical Pharmacology and Therapeutics, 1989, 45, 553-561.	2.3	20
114	Centers for Education and Research on Therapeutics report: Survey of medication errors education during undergraduate and graduate medical education in the United States. Clinical Pharmacology and Therapeutics, 2002, 71, 4-10.	2.3	20
115	Community Pharmacy Managers' Perception of Computerized Drugâ€"Drug Interaction Alerts. Journal of the American Pharmacists Association: JAPhA, 2006, 46, 148-153.	0.7	20
116	Medical decision support systems and therapeutics: The role of autopilots. Clinical Pharmacology and Therapeutics, 2016, 99, 161-164.	2.3	20
117	Class I antiarrhythmic agents: Quinidine, procainamide and N-acetylprocainamide, disopyramide. , 1983, 23, 179-191.		19
118	Relation between ventricular function and antiarrhythmic responses to sotalol. American Journal of Cardiology, 1989, 64, 943-945.	0.7	19
119	Pentamidine-induced torsades de pointes: Safe completion of therapy with inhaled pentamidine. Clinical Pharmacology and Therapeutics, 1991, 49, 698-700.	2.3	19
120	Evaluation of Warfarin Drug Interaction Listings in US Product Information for Warfarin and Interacting Drugs. Clinical Therapeutics, 2011, 33, 36-45.	1.1	19
121	Metabolism of L-Methionine-35S in Zinc-deficient Rats. Journal of Nutrition, 1972, 102, 1181-1186.	1.3	18
122	New insights into the definition and meaning of proarrhythmia during initiation of antiarrhythmic drug therapy from the cardiac arrhythmia suppression trial and its pilot study. Journal of the American College of Cardiology, 1994, 23, 1130-1140.	1.2	18
123	Workload and Availability of Technology in Metropolitan Community Pharmacies. Journal of the American Pharmacists Association: JAPhA, 2006, 46, 154-160.	0.7	18
124	Molecular basis for the antigenicity of lidocaine analogs: Tocainide and mexiletine. American Heart Journal, 1984, 107, 585-589.	1.2	17
125	Pharmacokinetic and Pharmacodynamic Interaction of N-Acetyl Procainamide and Procainamide in Humans. Journal of Cardiovascular Pharmacology, 1989, 14, 364-373.	0.8	17
126	d-Sotalol reduces heart rate in vivo through a Î²-adrenergic receptorâ€"independent mechanism. Clinical Pharmacology and Therapeutics, 1993, 53, 436-442.	2.3	17

#	Article	IF	Citations
127	Analysis of potential adverse drug reactionsâ€"A case of mistaken identity. American Journal of Cardiology, 1994, 74, 208-209.	0.7	17
128	Evidence for the biotransformation of procainamide to a reactive metabolite. Toxicology and Applied Pharmacology, 1979, 50, 9-16.	1.3	16
129	Importance of metabolites in antiarrhythmic therapy. American Journal of Cardiology, 1983, 52, C3-C7.	0.7	16
130	Tocainide plus quinidine for treatment of ventricular arrhythmias. American Journal of Cardiology, 1988, 61, 570-573.	0.7	16
131	Teaching objectives for fellowship programs in clinical electrophysiology. Journal of the American College of Cardiology, 1988, 12, 255-261.	1.2	16
132	Clinical pharmacokinetics of moricizine. American Journal of Cardiology, 1990, 65, 21-25.	0.7	16
133	Agranulocytosis During Combined Procainamide and Phenytoin Therapy. Southern Medical Journal, 1979, 72, 1599-1600.	0.3	15
134	CAST: Implications for drug development. Clinical Pharmacology and Therapeutics, 1990, 47, 553-556.	2.3	15
135	Determination of clemastine in human plasma by gas chromatography with nitrogenâ€"phosphorus detection. Biomedical Applications, 2000, 744, 177-181.	1.7	15
136	Identification of populations likely to benefit from pharmacogenomic testing. Pharmacogenetics and Genomics, 2020, 30, 91-95.	0.7	15
137	Role of plasma concentration monitoring in the evaluation of response to antiarrhythmic drugs. American Journal of Cardiology, 1988, 62, H9-H17.	0.7	14
138	S-Mephenytoin hydroxylation phenotypes in a Jordanian population*. Clinical Pharmacology and Therapeutics, 1995, 58, 542-547.	2.3	14
139	Discovering adverse reactions: Why does it take so long?. Clinical Pharmacology and Therapeutics, 2004, 76, 287-289.	2.3	14
140	Pharmacologic reversal of hypotensive effect complicating antiarrhythmic therapy with bretylium. Clinical Pharmacology and Therapeutics, 1982, 32, 313-321.	2.3	13
141	Electrophysiology of O-Demethyl Encainide in a Canine Model of Sustained Ventricular Tachycardia. Journal of Cardiovascular Pharmacology, 1984, 6, 588-595.	0.8	13
142	Lack of Triggered Automaticity Despite Repolarization Abnormalities due to Bepridil and Lidoflazine. PACE - Pacing and Clinical Electrophysiology, 1990, 13, 30-36.	0.5	13
143	The clinical value of FDA class C drugs approved from 1981 to 1988. Clinical Pharmacology and Therapeutics, 1992, 52, 577-582.	2.3	13
144	Clinical importance of metabolites of antiarrhythmic drugs. American Journal of Cardiology, 1984, 53, 248-251.	0.7	12

#	Article	IF	Citations
145	Clinical Pharmacokinetics of Encainide. Clinical Pharmacokinetics, 1988, 14, 141-147.	1.6	12
146	Indications for Antiarrhythmic Therapy: A Wealth of Controversy, A Dearth of Data. Annals of Internal Medicine, 1988, 108, 450.	2.0	12
147	Determination of dextromethorphan metabolic phenotype by salivary analysis with a reference to genotype in Chinese patients receiving renal hemodialysis*. Clinical Pharmacology and Therapeutics, 1996, 59, 411-417.	2.3	12
148	Clarification to the www.qtdrugs.org updated lists. Pharmacoepidemiology and Drug Safety, 2009, 18, 423-424.	0.9	12
149	Potential Applications of Free Drug Level Monitoring in Cardiovascular Therapyâ€. Clinical Pharmacokinetics, 1984, 9, 79-83.	1.6	11
150	Brief Report: Development of a prescription medication information webliography for consumers. Journal of General Internal Medicine, 2006, 21, 1313-1316.	1.3	11
151	Investigation of potential mechanisms of sex differences in quinidine-induced torsade de pointes risk. Journal of Electrocardiology, 2015, 48, 533-538.	0.4	11
152	Arrhythmogenic foods â€“ A growing medical problem. Trends in Cardiovascular Medicine, 2020, 30, 310-312.	2.3	11
153	Electropharmacologic Synergism With Mexiletine and Quinidine. Journal of Cardiovascular Pharmacology, 1987, 9, 840-846.	0.8	11
154	Control of ventricular preexcitation and associated arrhythmias by encainide. American Heart Journal, 1981, 102, 794-797.	1.2	10
155	Incremental Effects of Concurrent Pharmacotherapeutic Regimens for Heart Failure on Hospitalizations and Costs. Annals of Pharmacotherapy, 2005, 39, 1785-1791.	0.9	10
156	Bretylium: Relations between plasma concentrations and pharmacologic actions in high-frequency ventricular arrhythmias. American Journal of Cardiology, 1985, 55, 395-401.	0.7	9
157	Effects of Concentration and Steric Configuration of Propranolol on AV Conduction and Ventricular Repolarization in the Dog. Journal of Cardiovascular Pharmacology, 1981, 3, 692-703.	0.8	8
158	Indications for Different Modes of Surgical Therapy in Medically Refractory Ventricular Arrhythmias. Annals of Surgery, 1986, 203, 679-684.	2.1	8
159	Selection of an antiarrhythmic drug for a sudden-death-prevention trial. American Heart Journal, 1982, 103, 737-745.	1.2	7
160	The Antiarrhythmic Activity of Meobentine Sulfate in Man. Journal of Cardiovascular Pharmacology, 1984, 6, 650-656.	0.8	7
161	The development and testing of intravenous dosing regimens: Application to flecainide for the suppression of ventricular arrhythmias. Clinical Pharmacology and Therapeutics, 1988, 43, 499-508.	2.3	7
162	Survey of clinical pharmacology training in the United States and Canada. Clinical Pharmacology and Therapeutics, 1996, 60, 1-7.	2.3	7

#	Article	IF	Citations
163	Biological Sex Analysis in Clinical Research. Journal of Women's Health and Gender-Based Medicine, 2000, 9, 933-934.	1.7	7
164	LCâ€“MS Analysis of Sertraline and Its Active Metabolite in Human Serum Using a Silica Column with a Non-Aqueous Polar Mobile Phase. Chromatographia, 2011, 73, 749-754.	0.7	7
165	One Hundred Years of Drug Regulation: Where Do We Go from Here?. Annual Review of Pharmacology and Toxicology, 2013, 53, 255-273.	4.2	6
166	Regulatory and Reimbursement Innovation. Science Translational Medicine, 2013, 5, 176cm3.	5.8	6
167	Recurrent Ventricular Tachycardia in the Absence of Overt Heart Disease. Southern Medical Journal, 1981, 74, 1090-1094.	0.3	5
168	Recainam dose titration and pharmacokinetics in patients with resistant arrhythmias. Clinical Pharmacology and Therapeutics, 1989, 46, 324-334.	2.3	5
169	Immediate- versus controlled-release disopyramide: Importance of saturable binding. Clinical Pharmacology and Therapeutics, 1993, 54, 16-22.	2.3	5
170	From Bench to Bedside: Role of Gender-Based Therapeutics in the Clinical Care of Women. Journal of Women's Health, 1998, 7, 21-23.	0.9	5
171	Evolving Global Regulatory Science Through the Voluntary Submission of Data: A 2013 Assessment. Therapeutic Innovation and Regulatory Science, 2014, 48, 236-245.	0.8	5
172	Longitudinal prescribing patterns of psychotropic drugs in nursing home residents.. Experimental and Clinical Psychopharmacology, 1996, 4, 224-233.	1.3	4
173	Correction to "Geographic Variation in the Prescription of Schedule II Opioid Analgesics among Outpatients in the United States". Health Services Research, 2006, 41, 856-859.	1.0	4
174	When prescribing drugs, do medical doctors and healthcare professionals realize that their patient has the long QT syndrome?. European Heart Journal, 2019, 40, 3118-3120.	1.0	4
175	Antiarrhythmic Therapy: Clinical Pharmacology Update. Journal of Clinical Pharmacology, 1984, 24, 295-305.	1.0	3
176	Biomedical Research Funding: View of the National Caucus of Basic Biomedical Science Chairs. FASEB Journal, 1992, 6, 3133-3134.	0.2	3
177	Adenosine A1-receptor occupancy predicts A1-receptor antagonist effects of N-0861*. Clinical Pharmacology and Therapeutics, 1998, 64, 536-541.	2.3	3
178	Relationships Between Psychotropic Drug Dosage, Plasma Drug Concentration, and Prolactin Levels in Nursing Home Residents. Therapeutic Drug Monitoring, 2000, 22, 688-694.	1.0	3
179	The role of Internet-based registries in tandem with genetic screening for the study of drug-induced arrhythmias. Current Therapeutic Research, 2001, 62, 787-795.	0.5	3
180	Pharmacokinetics/Pharmacodynamics of Antiarrhythmic Drugs. Cardiac Electrophysiology Clinics, 2010, 2, 341-358.	0.7	3

#	Article	IF	Citations
181	Community pharmacy and pharmacist staff call center: Assessment of medication safety and effectiveness. Journal of the American Pharmacists Association: JAPhA, 2011, 51, 82-89.	0.7	3
182	Counterfeit drugs: A plot worthy of John le CarrÃ¨. International Journal of Cardiology, 2017, 243, 279-280.	0.8	3
183	Summary of Torsades de Pointes (TdP) Reports Associated with Intravenous Drug Formulations Containing the Preservative Chlorobutanol. Drug Safety, 2019, 42, 907-913.	1.4	3
184	Markers of ventricular repolarization and overall mortality in sleep disordered breathing. Sleep Medicine, 2022, 95, 9-15.	0.8	3
185	Mexiletine for resistant ventricular tachycardia: Comparison with lidocaine and enhancement of efficacy by combination with quinidine. American Journal of Cardiology, 1981, 47, 438.	0.7	2
186	Antiarrhythmic effects of the quaternary propranolol analog that does not induce beta-adrenergic blockade. Clinical Pharmacology and Therapeutics, 1982, 32, 33-40.	2.3	2
187	They Are From the Government and They Really Are Here to Help You. Journal of Clinical Pharmacology, 2008, 48, 142-143.	1.0	2
188	Time to Replace Bazett's QTâ€Correction. PACE - Pacing and Clinical Electrophysiology, 2009, 32, 1379-1380.	0.5	2
189	Assisted prescribing: Clinical decision support with MedSafety Scan now available. Trends in Cardiovascular Medicine, 2022, 32, 44-49.	2.3	2
190	The Integration of Pharmacodynamics and Pharmacokinetics in Rational Drug Development. , 1993, , 225-238.		2
191	Clinician Responses to a Clinical Decision Support Advisory for High Risk of Torsades de Pointes. Journal of the American Heart Association, 2022, 11, .	1.6	2
192	Influence of Theobromine Magnesium Oleate on Formation of Experimental Atheroma. Experimental Biology and Medicine, 1973, 143, 1098-1105.	1.1	1
193	Clinical significance of the ECG interval prolongation accompanying effective encainide therapy. American Journal of Cardiology, 1980, 45, 473.	0.7	1
194	Prospective pharmacokinetically based development of effective infusion regimens for ACCâ€“9358, a new antiarrhythmic drug. Clinical Pharmacology and Therapeutics, 1991, 49, 314-321.	2.3	1
195	Use of Drugs in Long QT Syndrome Type 3 and Brugada Syndrome. Cardiac Electrophysiology Clinics, 2014, 6, 811-817.	0.7	1
196	Farewell to our Good Friend and Outstanding Colleague David Flockhart (1952â€“2015). Clinical Pharmacology and Therapeutics, 2016, 99, 139-142.	2.3	1
197	Drug-Induced Long QT Syndrome and Torsades de Pointes. , 2020, , 185-200.		1
198	Abolition of ventricular arrhythmias during chronic oral therapy with encainide in man. American Journal of Cardiology, 1980, 45, 451.	0.7	0

#	Article	IF	Citations
199	Suppression of complex ventricular arrhythmias by timolol. American Journal of Cardiology, 1982, 49, 1018.	0.7	0
200	Efficacy and safety of ACC-9358, a new antiarrhythmic agent. American Journal of Cardiology, 1990, 65, 932-934.	0.7	0
201	Message from the Government Affairs Committee. Clinical Pharmacology and Therapeutics, 1996, 59, 486-488.	2.3	0
202	I.V. Amiodarone: What Do We Really Know About It?. Journal of Interventional Cardiac Electrophysiology, 1998, 2, 61-63.	0.9	0
203	Regulating manufacturer-affiliated communication in the information age. Clinical Pharmacology and Therapeutics, 1999, 65, 593-597.	2.3	0
204	The Translational Path Includes the FDA's Critical Path. Journal of Cardiovascular Translational Research, 2008, 1, 188-189.	1.1	0
205	It Is Important Research, but Why Is It Necessary?. Clinical Pharmacology and Therapeutics, 2013, 93, 297-299.	2.3	0
206	Prevalence and Correlates of Use of Medications Associated with Prolongation of the Corrected QT Interval in Older Adults. American Journal of Geriatric Psychiatry, 2017, 25, S145-S146.	0.6	0
207	Farewell to Our Good Friend, Outstanding Mentor, and Colleague Darrell R. Abernethy (1949â€“2017). Clinical Pharmacology and Therapeutics, 2018, 103, 552-555.	2.3	0
208	Linking Technology to Address the Social and Medical Determinants of Health for Safe Medicines Use. Journal of Patient Safety, 2021, Publish Ahead of Print, .	0.7	0
209	Investigating the Impact of Gadolinium-Based Contrast Agents on the Corrected QT Interval. Cureus, 2020, 12, e9668.	0.2	0
210	An Information Technology Architecture for Drug Effectiveness Reporting and Post-Marketing Surveillance. , 0, , 131-145.		0
211	Drug-induced torsades de pointes. , 2022, , 39-50.		0